Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine mechanisms in OCD (MKET2)
NCT05940324Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Feb 2024
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ketamine in obsessive compulsive disorder (OCD) (3 arms), sponsored by Stanford University. Primary endpoint: Yale-Brown Obsessive Compulsive Scale at 1 week. Started Feb 2024; status: recruiting.
02
Drugs
ketamine
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on NCT05940324.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940324.